Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of “Buy” by Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTVGet Free Report) have earned an average rating of “Buy” from the six ratings firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $21.00.

A number of research firms recently commented on ARTV. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright began coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective on the stock.

Check Out Our Latest Report on Artiva Biotherapeutics

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp purchased a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $1,337,000. Geode Capital Management LLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at $4,774,000. Barclays PLC bought a new position in Artiva Biotherapeutics in the 3rd quarter worth $304,000. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth about $42,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $623,000.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $5.56 on Friday. The business has a 50-day simple moving average of $10.02. Artiva Biotherapeutics has a twelve month low of $5.54 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTVGet Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Research analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

About Artiva Biotherapeutics

(Get Free Report

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

Featured Articles

Analyst Recommendations for Artiva Biotherapeutics (NASDAQ:ARTV)

Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.